ASRT:NSD-Assertio Holdings, Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSD

Last Closing Price

USD 0.66

Change

0.00 (0.00)%

Market Cap

USD 0.07B

Volume

0.50M

Average Target Price

USD 3.50 (+429.42%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Assertio Holdings, Inc. operates as a specialty pharmaceutical company in the United States. Its specialty pharmaceutical products include CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for treating migraine; Zipsor, an NSAID for relief of mild to moderate acute pain; Gralise, a once-daily formulation of gabapentin for the management of postherpetic neuralgia; NUCYNTA ER, an extended-release version of tapentadol for the management of neuropathic pain associated with diabetic peripheral neuropathy; and NUCYNTA IR, an immediate release version of tapentadol for the management of moderate to severe acute pain. The company has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD7.45B 26.81 7.09
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.23B N/A N/A
PCRX Pacira BioSciences, Inc

N/A

USD2.52B 870.20 73.37
CRON Cronos Group Inc

N/A

USD1.77B 2.44 N/A
IRWD Ironwood Pharmaceuticals, Inc

N/A

USD1.51B 15.26 12.72
APHA Aphria Inc

N/A

USD1.22B 57.50 392.34
ATNX Athenex, Inc

N/A

USD1.14B N/A N/A
SUPN Supernus Pharmaceuticals, Inc

N/A

USD1.07B 9.18 5.84
PETQ PetIQ, Inc

N/A

USD0.91B 134.36 111.60
AMPH Amphastar Pharmaceuticals, Inc

N/A

USD0.86B 224.88 27.46

ETFs Containing ASRT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -47.11% 33% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.11% 33% F 13% F
Trailing 12 Months  
Capital Gain -49.53% 31% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.53% 31% F 11% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -38.48% N/A N/A 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.48% N/A N/A 2% F
Risk Return Profile  
Volatility (Standard Deviation) 37.54% N/A N/A 35% F
Risk Adjusted Return -102.50% N/A N/A 3% F
Market Capitalization 0.07B 31% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 10.00 68% D+ 69% D+
Price/Book Ratio 0.82 90% A- 79% C+
Price / Cash Flow Ratio 0.78 34% F 56% F
EV/EBITDA 3.87 88% B+ 85% B
Management Effectiveness  
Return on Equity -129.29% 32% F 10% F
Return on Invested Capital -31.64% 47% F 24% F
Return on Assets -4.28% 62% D- 33% F
Debt to Equity Ratio 468.03% 5% F 3% F
Technical Ratios  
Short Ratio 2.18 69% D+ 60% D-
Short Percent 1.34% 86% B 73% C
Beta 2.06 15% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector